Bone Marrow – Fibrosis

Figure Legend: Figure 1 Dense fibrous tissue surrounded by areas of angiectasis is present in bone marrow in a male F344/N male rat from a chronic study. Figure 2 Higher magnification of Figure 1 showing dense fibrous tissue surrounded by areas of angiectasis in bone marrow from a male F344/N rat in a chronic study. Figure 3 Higher magnification of Figure 1 showing dense fibrous tissue surrounded by areas of angiectasis in bone marrow from a male F344/N rat in a chronic study.

Comment: Bone marrow fibrosis is a lesion characterized by an increase of reticulin fibers or reticulin and collagen fibers, and/or proliferating fibroblasts. It is a secondary change associated with such disorders as inflammation, bone marrow necrosis, bone marrow injury, and disorders.
Bone Marrow – Fibrosis

of myeloproliferation (e.g., acute myeloid leukemia) and lymphoproliferation (e.g., lymphoma).

Fibrosis can be focal, multifocal, or diffuse and range from a mild increase in fibroblasts, with the presence of scattered, loose eosinophilic collagen/reticulin fibers, to dense fibrosis tissue (Figures 1–3). Modest increases in reticulin fibers can be difficult to appreciate but can be confirmed with a silver impregnation technique, such as Gomori stain. Collagen fibers are identified as eosinophilic fibers that may be in bundles and are confirmed with the use of a trichrome stain (e.g., Mallory’s or Masson’s).

While it is not clear in rodent toxicity or preclinical studies if there is a need to distinguish among fibrosis types, much has been recently learned in humans regarding this topic. In humans, increased reticulin fibers are associated with many benign and malignant conditions, while increased collagen is prominent in late stages of myeloproliferative diseases or following metastasis to the bone marrow. The amount of reticulin staining in the bone marrow often has no correlation with disease severity, while increases in collagen staining are associated with more severe disease and a poorer prognosis. In addition, reticulin fibrosis is more likely to reverse than is collagen fibrosis after removal or successful treatment of the causative disorder.

Although much about the pathophysiology of (secondary) bone marrow fibrosis remains to be elucidated, it is known that cytokines from bone marrow macrophages, megakaryocytes, and platelets appear to be necessary for fibrosis to occur. These include platelet-derived growth factor and transforming growth factor-β. Additionally, fibrosis has been induced in mice injected with high amounts of recombinant thrombopoietin.

**Recommendation:** Fibrosis (secondary) should be diagnosed and graded in subchronic and chronic studies only when it is a prominent feature of a lesion. Severity is based on the extent of the fibrosis, and if considered to be important to the study or a treatment-related change, the pattern should be described in the pathology narrative.
The fibroproliferative and osteosclerotic lesions of fibrous osteodystrophy and fibro-osseous lesions are well-defined lesions of rodent bone with distinct histologic characteristics (see the chapter on bone). Thus, it is inappropriate to use the term “fibrosis” to diagnose these lesions.

The diagnostic term “myelofibrosis” should not be used to describe fibrotic lesions of the bone marrow in mice and rats. In humans, myelofibrosis is an abbreviated term that has been used in reference to chronic idiopathic myelofibrosis or primary myelofibrosis. This disease is a distinct clonal myeloproliferative disease characterized by a reactive, progressive fibrosis occurring in response to a neoplastic myeloid and/or megakaryocytic proliferation and is accompanied by specific hematologic and clinical findings. Since a similar disorder has not been documented in rodents, it is best to avoid use of the term “myelofibrosis.”

References:


Authors:

Michelle C. Cora, DVM, DACVP
Veterinary Medical Officer
NTP Clinical Pathologist
NTP Clinical Pathology Group
National Institute of Environmental Health Sciences
Research Triangle Park, NC

Gregory Travlos, DVM, DACVP
Group Leader, Clinical Pathology Group
Cellular and Molecular Pathology Branch
National Institute of Environmental Health Sciences
Research Triangle Park, NC